Rheumatoid Arthritis Molecular Subtyping via Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating rheumatoid arthritis (RA) are imprecise and lack effective biomarkers for identifying disease presence, clinical activity, response to therapy, and prognosis, leading to trial-and-error treatment approaches that can be risky and uncomfortable for patients.
Innovation Solution
The identification of four distinct molecular phenotypes (subtypes) of RA, including lymphoid-rich, myeloid-rich, fibroblast-rich type 2, and fibroblast-rich type 1, based on differential gene expression, which serve as therapeutic targets and diagnostic markers, allowing for the measurement of specific genes and proteins to classify subtypes and predict treatment responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current laboratory tests (RF, anti-CCP, ESR, CRP) and ACR criteria are used for diagnosing RA, then diagnosis can be made based on available methods, but the diagnosis is imprecise and imperfect
Solution Approach 1:
The invention segments RA into four distinct molecular subtypes (F1, F2, L, M) based on gene expression profiles. This segmentation allows for more precise diagnosis by identifying specific molecular characteristics of each subtype, moving beyond the traditional binary diagnostic approach to a more nuanced classification that improves both precision and reliability of RA diagnosis.
Solution Approach 2:
The invention introduces new diagnostic parameters by measuring gene expression levels of specific genes (such as ITGA11, MMP11, MMP13 for F1 subtype; FGF10, FGF18, FGF2 for F2 subtype; CXCL13, FcRH5 for L subtype; and various myeloid-related genes for M subtype). These parameter changes enable more accurate differentiation between RA subtypes and improve diagnostic precision compared to traditional markers.
2Adaptability or versatility
If trial-and-error treatment approaches are used for RA, then treatment options can be explored, but the process is risky and uncomfortable for patients
Solution Approach 1:
The invention performs preliminary classification of RA patients into molecular subtypes before treatment initiation. By measuring gene expression profiles to identify specific subtypes (F1, F2, L, or M), clinicians can select targeted therapies appropriate for each subtype beforehand, eliminating the need for trial-and-error approaches and improving treatment effectiveness from the start.
Solution Approach 2:
The invention applies local quality by providing subtype-specific treatment recommendations tailored to each molecular subtype's characteristics. For example, F1 subtype (fibroblast-rich type 1) targets specific fibroblast-related pathways, while L subtype (lymphoid-rich) targets lymphoid-related pathways. This localized treatment approach improves reliability by matching therapy to the specific molecular profile of each patient's disease.
3Measurement precision
If molecular subtyping based on gene expression is implemented, then precise diagnosis and personalized treatment are enabled, but the complexity of the diagnostic system increases
Solution Approach 1:
The diagnostic system is segmented into four distinct molecular subtype categories (F1, F2, L, M), each with defined gene expression characteristics. This segmentation simplifies the complex task of RA classification by providing clear, discrete categories with specific gene signatures, making the system more manageable while maintaining high precision in subtype identification.
Data Source
AI summary
Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.